Fatal candidemia caused by azole-resistant Candida tropicalis in patients with hematological malignancies

被引:30
作者
Chong, Yong [1 ]
Shimoda, Shinji [2 ]
Yakushiji, Hiroko [3 ]
Ito, Yoshikiyo [1 ]
Miyamoto, Toshihiro [2 ]
Shimono, Nobuyuki [4 ]
Kamimura, Tomohiko [1 ]
Akashi, Koichi [2 ]
机构
[1] Hara Sanshin Hosp, Dept Blood & Marrow Transplantat, Hakata Ku, Fukuoka 8120033, Japan
[2] Kyushu Univ, Grad Sch Med Sci, Fukuoka 812, Japan
[3] Hara Sanshin Hosp, Dept Clin Lab, Fukuoka, Japan
[4] Kyushu Univ Hosp, Ctr Study Global Infect, Fukuoka 812, Japan
关键词
Candida tropicalis; Azole; Resistance; Candidemia; BREAKTHROUGH FUNGEMIA; ANTIFUNGAL AGENTS; RISK-FACTORS; FLUCONAZOLE; SUSCEPTIBILITY; VORICONAZOLE; SURVEILLANCE; COLONIZATION; CASPOFUNGIN; RESERVOIR;
D O I
10.1007/s10156-012-0412-9
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Candida tropicalis is one of the most important Candida species causative of candidemia that is isolated from the blood of patients with hematological malignancies. Candidemia caused by C. tropicalis is known to be highly virulent in neutropenic patients. C. tropicalis has been shown to be favorably sensitive to azole agents in general. Here we discuss 5 cases of candidemia caused by C. tropicalis in patients with hematological malignancies in our unit, and we note that 4 isolates were resistant to azole agents, including fluconazole, itraconazole, and voriconazole. In addition, 2 patients developed breakthrough candidemia caused by C. tropicalis while receiving prophylaxis with azole agents. Interestingly, 2 of the 4 patients with azole-resistant C. tropicalis isolates had never received any antifungal drugs. We also examined the susceptibilities of C. tropicalis to antifungal agents, using 39 non-blood isolates detected from 2003 to 2009. Around 40 % of the isolates were resistant to azole agents, and all of them were highly sensitive to amphotericin B and micafungin. The resistance to azoles was not associated with previous exposure to those agents. In our unit, 2 of the 4 cases of candidemia caused by azole-resistant C. tropicalis resulted in a poor prognosis. These findings suggested that empirical therapeutic strategies for candidemia should be modified based on the local antifungal resistance pattern.
引用
收藏
页码:741 / 746
页数:6
相关论文
共 32 条
[1]  
[Anonymous], 2008, Approved standard M27-A. A National Committee for Clinical Laboratory Standards
[2]   Fatal Candida tropicalis fungaemia in a leukaemic patient receiving fluconazole prophylaxis [J].
Barnes, AJ ;
Wardley, AM ;
Oppenheim, BA ;
Morgenstern, GR ;
Scarffe, JH ;
Warnock, DW ;
Johnson, EM .
JOURNAL OF INFECTION, 1996, 33 (01) :43-45
[3]  
Clinical Laboratory Standards Institute, 2008, M27S3 CLSI
[4]   The role of the intestinal tract as a reservoir and source for transmission of nosocomial pathogens [J].
Donskey, CJ .
CLINICAL INFECTIOUS DISEASES, 2004, 39 (02) :219-226
[5]   Caspofungin-Resistant Candida tropicalis Strains Causing Breakthrough Fungemia in Patients at High Risk for Hematologic Malignancies [J].
Garcia-Effron, Guillermo ;
Kontoyiannis, Dimitrios P. ;
Lewis, Russell E. ;
Perlin, David S. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2008, 52 (11) :4181-4183
[6]   Risk Factors for Fluconazole-Resistant Candidemia [J].
Garnacho-Montero, Jose ;
Diaz-Martin, Ana ;
Garcia-Cabrera, Emilio ;
Perez de Pipaon, Maite Ruiz ;
Hernandez-Caballero, Clara ;
Aznar-Martin, Javier ;
Cisneros, Jose M. ;
Ortiz-Leyba, Carlos .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (08) :3149-3154
[7]  
Jang SJ, 2005, JPN J INFECT DIS, V58, P263
[8]   Risk factors for Candida tropicalis fungemia in patients with cancer [J].
Kontoyiannis, DP ;
Vaziri, I ;
Hanna, HA ;
Boktour, M ;
Thornby, J ;
Hachem, R ;
Bodey, GP ;
Raad, II .
CLINICAL INFECTIOUS DISEASES, 2001, 33 (10) :1676-1681
[9]   Triazole cross-resistance among candida spp.: Case report, occurrence among bloodstream isolates, and implications for antifungal therapy [J].
Magill, SS ;
Shields, C ;
Sears, CL ;
Choti, M ;
Merz, WG .
JOURNAL OF CLINICAL MICROBIOLOGY, 2006, 44 (02) :529-535
[10]   Activity of Contemporary Antifungal Agents, Including the Novel Echinocandin Anidulafungin, Tested against Candida spp., Cryptococcus spp., and Aspergillus spp.: Report from the SENTRY Antimicrobial Surveillance Program (2006 to 2007) [J].
Messer, Shawn A. ;
Moet, Gary J. ;
Kirby, Jeffrey T. ;
Jones, Ronald N. .
JOURNAL OF CLINICAL MICROBIOLOGY, 2009, 47 (06) :1942-1946